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been shown by antibody characterization in patients, antigen-
speci®c serum adsorption studies, genetics, animal models of both
passive and active induction of disease, and speci®c cleavage of
desmoglein 1 by a protease (Stanley et al, 2001). As in all diseases,
there may be alternative pathophysiologic mechanisms in some
cases, but at this point there is no convincing evidence for
antiacetylcholine receptor antibodies as a cause of pemphigus. In
short, we stand by our previous editorial (Stanley et al, 2001).
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Possible Role for Non-Desmoglein Antigen in Pemphigus
To the Editor:
The editorial ``Pemphigus: is there another half of the story?'', by
Stanley et al (2001), signals a healthy controversy regarding the
pathogenesis of pemphigus vulgaris. Despite the solid evidence that
antidesmoglein (Dsg) antibodies have the central role in pemphigus
vulgaris (PV) and foliaceous (PF), recent data raise questions that
need to be addressed (Kalish, 2000). Data supporting a role for non-
Dsg autoantigens in pemphigus include the following (Nguyen et
al, 2000):
(1) PV sera devoid of anti-Dsg1 activity produce blisters in
Dsg3(±/±) mice. Dsg3(±/±) mice develop few spontaneous
erosions, but with injection of this PV sera develop massive bullae,
similar to those in Dsg3(+/+) mice. This con®rms the importance
of inactivating Dsg3 to produce PV-like blisters, but also indicates
that anti-Dsg are not the sole pathogenic antibodies in PV sera.
(2) PV sera immunoprecipitates multiple non-Dsg antigens from
both normal and Dsg3 (±/±) keratinocytes, including a antigen (not
Dsg3) that migrates at 130 kDa.
(3) Absorption of PV sera with Dsg3-Ig fusion protein removes
pathogenicity; however, antibodies eluted from this column react
with multiple antigens from both Dsg3(±/±) and normal keratino-
cytes. This was clearly demonstrated with western blots using
eluted antibodies.
The only discrepancy between the data of Nguyen et al (2000)
and that of John Stanley (Mahoney et al, 1999) relates to the site of
blister formation in desmoglein (±/±) mice that receive PF sera.
The solution is to repeat these experiments with shared reagents.
This discrepancy is not critical to the overall interpretation of the
data, as Nguyen demonstrates, by several different sensitive assays,
that the PV sera used lacks anti-Dsg1 activity.
The above data suggest that PV is mediated by additional
autoantibodies acting in concert with anti-Dsg. It is theorized that
antibodies to keratinocyte cholinergic receptors may be the missing
component (Nguyen et al, 2000). This last point is not proven, but
is based on data, and should not be lightly dismissed. I have very
high regard for all the investigators involved, and eagerly await
additional scienti®c developments.
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Expression of Basal-Cell Adhesion Molecule (B-CAM) is
Associated with Immature States of Human Keratinocytes
To the Editor:
We thank Dr. Boehncke for his interest and comments
regarding our work. Unfortunately, his group's publication
(Bernemann et al, 2000) was not yet available to us at the time
our manuscript was prepared and submitted. While we found
B-CAM reactivity preferentially within the basal epidermal layer
in in¯ammatory disorders or epithelial skin tumors (SchoÈn et al,
2000), Dr. Boehncke proposed B-CAM as a marker for
terminal differentiation of human keratinocytes based upon
suprabasal antibody binding in a subset of normal human skin
biopsies (Bernemann et al, 2000). Another study reports ``weak
and variable'' B-CAM expression in the upper layers of the
epidermis without specifying number or origin of the specimens
tested (Garin-Chesa et al, 1994). The same study reports
polarized basal expression of B-CAM in other strati®ed
epithelia, such as esophagus or uterine cervix. The latter and
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our observations are consistent with its role as a laminin
receptor of basal epithelial, endothelial, and tumor cells (hence
the name basal cell adhesion molecule) (Feickert et al, 1990;
Campbell et al, 1994). We can currently not perceive of a
potential biologic role of a laminin-binding receptor constitu-
tively expressed by terminally differentiated keratinocytes; how-
ever, it is conceivable that differences regarding suprabasal
staining seen in some specimens in two studies when using the
G253 monoclonal antibody (MoAb) may be due to certain
technical details. In these studies, a single MoAb, G253, was
used as culture supernatant without identi®cation of additional
components of this mixture (e.g., serum constituents, cellular
proteins, or proteinases of hybridoma cells), the ®nal concen-
tration of the MoAb used has not been determined, and
negative or positive controls using similar supernatant containing
isotype-matched MoAb were not mentioned (Garin-Chesa et al,
1994; Bernemann et al, 2000). In contrast, in another study
de®ned concentrations (10 mg per ml) of two different af®nity-
puri®ed MoAb (G253 and VF18) in a de®ned vehicle (PBS)
were used, negative controls with isotype-matched mouse IgG
were performed, and positive controls with identical concen-
trations of isotype-matched MoAb recognizing unrelated mem-
brane proteins of human keratinocytes were carried out (SchoÈn
et al, 2000). In our hands, weak and inconsistent suprabasal
staining of normal human epidermis was only observed when
using very high concentrations of the G253 MoAb (> 20 mg
per ml), but not the VF18 MoAb. As a consequence of the
technical differences, it is not easy to compare the results of the
studies and to discern why some specimens of normal adult skin
showed suprabasal reactivity, whereas others did not; however,
the important question was raised whether B-CAM may be a
marker of terminal differentiation of human keratinocytes. First,
we would like to comment on an apparent misconception: In
our paper (SchoÈn et al, 2000), we have demonstrated that B-
CAM is markedly down-regulated by approximately 80% when
Ca2+ levels were elevated in cultures of human keratinocytes.
As Ca2+ is known to induce terminal differentiation of
keratinocytes (Pillai et al, 1990), this observation strongly
suggested a correlation of B-CAM with undifferentiated or
immature states of human keratinocytes, at least in vitro, rather
than terminally differentiated keratinocytes as proposed in Dr.
Boehncke's letter.
Moreover, we have performed additional experiments to
further address this question: as terminal differentiation of
human keratinocytes is a process that ultimately leads to
apoptosis, we assessed B-CAM expression in mock (vector
only)-transfected and bcl-2-transfected HaCaT cells (generously
provided by Dr. C. C. Geilen, Free University of Berlin), the
latter being largely resistant to apoptosis (MuÈller-Wieprecht et
al, 2000). As demonstrated by western-blot analysis (three
independent experiments), HaCaT cells overexpressing bcl-2
showed markedly higher B-CAM expression as compared with
their mock-transfected counterparts (Fig 1A). This was con-
®rmed in ®ve independent FACS experiments showing an
approximately 2-fold higher surface expression of B-CAM in
bcl-2 transfectants (Fig 1C). These results did not support the
hypothesis of an association of B-CAM with terminal differen-
tiation of human keratinocytes, but corroborated our previous
results demonstrating downregulation of B-CAM by cytostatic
compounds that confer their action, at least in part, through
induction of apoptosis (SchoÈn et al, 2000).
In another series of experiments, B-CAM expression was
assessed in a nontumorigenic ras-transfected HaCaT line (A/4)
and a malignant ras-transfected HaCaT line (II/3; Fusenig and
Boukamp, 1998). Both cell lines were kindly provided by Dr.
N.E. Fusenig (German Cancer Research Center, Heidelberg).
Again, as detected by both western blot (Fig 1B) and FACS
analysis (Fig 1D), B-CAM expression was markedly higher in
the malignant HaCaT-ras transfectants as compared with the
nontumorigenic line. These results suggested an association of
B-CAM with the tumorigenic and/or metastatic potential of
these cells. Overall, we think that there is some circumstantial
evidence for an association of B-CAM with undifferentiated or
immature states of human keratinocytes rather than terminal
differentiation.
Margarete SchoÈn, Michael P. SchoÈn
Department of Dermatology, Otto-von-Guericke University,
Magdeburg, Germany
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Expression of Basal-Cell Adhesion Molecule (B-CAM) in
Human Epidermis
To the Editor:
I read with interest the recent article by SchoÈn et al on the
expression of basal-cell adhesion molecule (B-CAM) in human skin
(SchoÈn et al, 2000) documenting association of B-CAM expression
with activated states of keratinocytes. The authors provide
convincing evidence that, besides its known function as a laminin
receptor, B-CAM may be involved in cell±cell interaction or
migration.
In this context I would like to bring to your attention data
regarding B-CAM expression in human skin that might not have
been accessible to the authors at the time their manuscript was
submitted. We have been analyzing B-CAM expression in normal
and diseased human skin utilizing the monoclonal antibody G253
that has also been employed in the paper by SchoÈn et al. Contrary
to their observation, but in line with previous ®ndings (Garin-
Chesa et al, 1994), the majority of specimen from normal human
epidermis exhibited B-CAM positive suprabasal keratinocytes. In
contrast, B-CAM expression in fetal epidermis was restricted to
basal keratinocytes. The outer root sheath of hair follicles in both
fetal as well as adult human skin regularly exhibited a B-CAM
positive phenotype. The level of B-CAM expression was higher in
psoriasis and contact dermatitis. We interpret our observations as
evidence for B-CAM being a keratinocyte differentiation marker
(Bernemann et al, 2000). This notion is supported by the effects of
Ca2+ levels on the B-CAM phenotype of keratinocytes as described
by SchoÈn et al.
Wolf-Henning Boehncke
Department of Dermatology, Frankfurt University
Medical School, Frankfurt, Germany
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Maternal Transmission of the 3 bp Deletion within Exon 7 of
the STS Gene in Steroid Sulfatase De®ciency
To the Editor:
Steroid sulfatase (STS) enzyme (EC 3.1.6.2) is present in the
microsomal fraction of the cell and is capable of hydrolyzing
sulfated sterols (Hobkirk, 1985; Dibbelt and Kuss, 1991). STS
de®ciency is the biochemical defect in X-linked ichthyosis (XLI), a
disease that clinically presents dark, adhesive, and regular scales of
skin (Shapiro and Weiss, 1978). STS assay or FISH analyzes allow
an XLI diagnosis and identify XLI-carriers (Baden et al, 1980;
Epstein and Leventhal, 1981; Okano et al, 1985; Hermann et al,
1987; Matsumoto et al, 1990; Aviram-Goldring et al, 2000). STS
enzyme is encoded by the STS gene on the short arm of the
X-chromosome (Muller et al, 1981). Most STS enzyme de®cient
patients present large deletions of the entire STS gene and ¯anking
sequences (Bonifas et al, 1987; Shapiro et al, 1989; Cuevas-
Covarrubias et al, 1997; Aviram-Goldring et al, 2000). Only a few
point mutations or partial deletions have been identi®ed (Bonifas
et al, 1987; Ballabio et al, 1989; Shapiro et al, 1989; Basler et al,
1992; Nomura et al, 1995; Alperin and Shapiro, 1997; Morita et al,
1997; Aviram-Goldring et al, 2000; Oyama et al, 2000; Sugawara et
al, 2000; Valdes et al, 2000). In this study, we describe an XLI
patient with the ®rst 3 bp intragenic deletion of the STS gene
causing XLI and demonstrate the maternal transmission of this
molecular defect.
MATERIALS AND METHODS
Patient The patient was referred as having ichthyosis to the General
Hospital of Mexico. He was the only child of the family. The patient
and his mother were informed about the characteristics of the study and
they agreed to participate. Protocol was evaluated and approved by the
Ethics Committee. The patient showed a moderate degree of
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